Yago Garitaonaindia MD
@ygaritaonaindia.bsky.social
Medical Oncologist | Thoracic & Melanoma
Immuno-Oncology | Translational & Real-World Evidence
TIL biology and cross-tumour IO research
CCIT-DK, Copenhagen
Immuno-Oncology | Translational & Real-World Evidence
TIL biology and cross-tumour IO research
CCIT-DK, Copenhagen
We’ve been discussing this paper for weeks.
Now the phase 3 trial in @natureportfolio.nature.com
carries an editor’s note after concerns raised online - “social media peer review” 🚩🚩
🔎 Social media amplification requires critical judgment
Now the phase 3 trial in @natureportfolio.nature.com
carries an editor’s note after concerns raised online - “social media peer review” 🚩🚩
🔎 Social media amplification requires critical judgment
February 20, 2026 at 8:50 AM
We’ve been discussing this paper for weeks.
Now the phase 3 trial in @natureportfolio.nature.com
carries an editor’s note after concerns raised online - “social media peer review” 🚩🚩
🔎 Social media amplification requires critical judgment
Now the phase 3 trial in @natureportfolio.nature.com
carries an editor’s note after concerns raised online - “social media peer review” 🚩🚩
🔎 Social media amplification requires critical judgment
Honoured to join @JNCI_NOW as Social Media Editor 🚀
Excited to contribute to the digital voice of JNCI Journals and help amplify clinically relevant research with global impact.
Scientific publishing is evolving and context & community matter more than ever
#Oncology #SciComm
Excited to contribute to the digital voice of JNCI Journals and help amplify clinically relevant research with global impact.
Scientific publishing is evolving and context & community matter more than ever
#Oncology #SciComm
February 19, 2026 at 7:49 AM
Does TIGIT benefit no one…
Or does it benefit a biologically defined subset we failed to identify? 🤔
All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts.
Is it time for true precision IO? 🔬
#ImmunoOncology #PrecisionMedicine #Biomarkers
Or does it benefit a biologically defined subset we failed to identify? 🤔
All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts.
Is it time for true precision IO? 🔬
#ImmunoOncology #PrecisionMedicine #Biomarkers
TIGIT’s immuno-oncology teachings
www.nature.com/articles/d41...
Drug developers spent billions of dollars on clinical trials of TIGIT-blocking cancer immunotherapies, but have little to show for it. What went wrong?
www.nature.com/articles/d41...
Drug developers spent billions of dollars on clinical trials of TIGIT-blocking cancer immunotherapies, but have little to show for it. What went wrong?
February 18, 2026 at 6:09 PM
Does TIGIT benefit no one…
Or does it benefit a biologically defined subset we failed to identify? 🤔
All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts.
Is it time for true precision IO? 🔬
#ImmunoOncology #PrecisionMedicine #Biomarkers
Or does it benefit a biologically defined subset we failed to identify? 🤔
All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts.
Is it time for true precision IO? 🔬
#ImmunoOncology #PrecisionMedicine #Biomarkers
New here on Bluesky 🚀
Medical oncologist focused on clinical research, IO and translational science
#Oncology #TranslationalResearch #Cancer
Medical oncologist focused on clinical research, IO and translational science
#Oncology #TranslationalResearch #Cancer
February 18, 2026 at 3:38 PM
New here on Bluesky 🚀
Medical oncologist focused on clinical research, IO and translational science
#Oncology #TranslationalResearch #Cancer
Medical oncologist focused on clinical research, IO and translational science
#Oncology #TranslationalResearch #Cancer